000 05117naa a22005777i 4500
001 UMUN-OA-20261005-PPE-060
003 local
005 20261005174856.0
006 m o d
007 cr||||||||||||
008 261005s2020 xx o u000 0 eng d
024 7 _a10.1186/s12916-020-01753-0
_2doi
035 _a(local)OpenAlex:W3094622981
040 _alocal
_beng
_clocal
041 0 _aeng
100 0 _aRuth P. Norris
_eauthor.
245 1 0 _aAre there socio-economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta-analysis /
_cRuth P. Norris; Rosie Dew; Linda Sharp [and others].
264 1 _a[Place of publication not identified] :
_bBioMed Central,
_c2020.
300 _a1 online resource (1 article).
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
500 _aPublication type: Review article.
500 _aLinked open-access copy: published version.
506 0 _aOpen access; no subscription required for the linked open-access version.
_fUnrestricted online access
_2star
520 3 _aBACKGROUND: Novel biological and precision therapies and their associated predictive biomarker tests offer opportunities for increased tumor response, reduced adverse effects, and improved survival. This systematic review determined if there are socio-economic inequalities in utilization of predictive biomarker tests and/or biological and precision cancer therapies. METHODS: MEDLINE, Embase, Scopus, CINAHL, Web of Science, PubMed, and PsycINFO were searched for peer-reviewed studies, published in English between January 1998 and December 2019. Observational studies reporting utilization data for predictive biomarker tests and/or cancer biological and precision therapies by a measure of socio-economic status (SES) were eligible. Data was extracted from eligible studies. A modified ISPOR checklist for retrospective database studies was used to assess study quality. Meta-analyses were undertaken using a random-effects model, with sub-group analyses by cancer site and drug class. Unadjusted odds ratios (ORs) and 95% confidence intervals (CIs) were computed for each study. Pooled utilization ORs for low versus high socio-economic groups were calculated for test and therapy receipt. RESULTS: Among 10,722 citations screened, 62 papers (58 studies; 8 test utilization studies, 37 therapy utilization studies, 3 studies on testing and therapy, 10 studies without denominator populations or which only reported mean socio-economic status) met the inclusion criteria. Studies reported on 7 cancers, 5 predictive biomarkers tests, and 11 biological and precision therapies. Thirty-eight studies (including 1,036,125 patients) were eligible for inclusion in meta-analyses. Low socio-economic status was associated with modestly lower predictive biomarker test utilization (OR 0.86, 95% CI 0.71-1.05; 10 studies) and significantly lower biological and precision therapy utilization (OR 0.83, 95% CI 0.75-0.91; 30 studies). Associations with therapy utilization were stronger in lung cancer (OR 0.71, 95% CI 0.51-1.00; 6 studies), than breast cancer (OR 0.93, 95% CI 0.78-1.10; 8 studies). The mean study quality score was 6.9/10. CONCLUSIONS: These novel results indicate that there are socio-economic inequalities in predictive biomarker tests and biological and precision therapy utilization. This requires further investigation to prevent differences in outcomes due to inequalities in treatment with biological and precision therapies.
540 _aCreative Commons Attribution (licence family recorded by the source; version not supplied in metadata).
_uhttps://openalex.org/W3094622981
546 _aIn English.
588 0 _aDescription generated from OpenAlex bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 _aCourse allocation: B. Sc. Politics, Philosophy and Economics.
650 4 _asocioeconomic disparities
650 4 _aprecision oncology
650 4 _ahealth care utilization
650 4 _ahealth disparities
650 4 _alung cancer
650 4 _abreast cancer
653 _aB. Sc. Politics, Philosophy and Economics
653 _aUMUN open access collection
653 _aeconomic inequality
655 4 _aReview articles.
700 0 _aRosie Dew
_eauthor.
700 0 _aLinda Sharp
_eauthor.
700 0 _aAlastair Greystoke
_eauthor.
700 0 _aStephen Rice
_eauthor.
700 0 _aKristina Johnell
_eauthor.
700 0 _aAdam Todd
_eauthor.
773 0 _tBMC Medicine
_gVol. 18, no. 1, (2020), pages/article 282
_x1741-7015
856 4 0 _uhttps://bmcmedicine.biomedcentral.com/track/pdf/10.1186/s12916-020-01753-0
_yRead open-access publication
_zOpen access. Access and licence reported by the source; this host could not be independently checked by automation.
_70
884 _aCourse selection and automated MARC21 enrichment from OpenAlex metadata.
_g20261005
_khttps://openalex.org/W3094622981
_qlocal
942 _n0
999 _c1072
_d1072